STUELPNAGEL JOHN R 4
4 · 10x Genomics, Inc. · Filed Nov 18, 2021
Insider Transaction Report
Form 4
STUELPNAGEL JOHN R
Director
Transactions
- Sale
Class A Common Stock
2021-11-16$157.55/sh−800$126,038→ 355,816 total - Sale
Class A Common Stock
2021-11-16$159.80/sh−1,048$167,472→ 351,716 total - Sale
Class A Common Stock
2021-11-16$158.79/sh−3,052$484,623→ 352,764 total - Sale
Class A Common Stock
2021-11-16$160.32/sh−100$16,032→ 351,616 total
Footnotes (4)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $157.02 to $157.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $158.19 to $159.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]This transaction was executed in multiple trades at prices ranging from $159.23 to $160.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.